Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term PACLITAXEL. Found 12 abstracts

Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU international. 2014 May;113(5B):E137-E143.
Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, Wong JT. Risk stratification for desensitization of patients with carboplatin hypersensitivity: Clinical presentation and management. Journal of Allergy and Clinical Immunology. 2009 Jun;123(6):1262-7.
Tian CQ, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, Rose PG, Spriggs D, Armstrong DK, Gynecologic Oncology Grp Study; Gynecologic Oncology Grp S. CA-125 Change After Chemotherapy in Prediction of Treatment Outcome Among Advanced Mucinous and Clear Cell Epithelial Ovarian Cancers A Gynecologic Oncology Group Study. Cancer. 2009 Apr;115(7):1395-403.   PMCID: PMC 2743569
Zorn KK, Tian CQ, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK. The Prognostic Value of Pretreatment CA 125 in Patients With Advanced Ovarian Carcinoma A Gynecologic Oncology Group Study. Cancer. 2009 Mar;115(5):1028-35.   PMCID: PMC 2664510
Darcy KM, Brady WE, McBroom JW, Bell JG, Young RC, McGuire WP, Linnolia RI, Hendricks D, Bonome T, Farley JH. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008 Dec;111(3):487-95.
Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, Hensley ML, Spriggs DR, Aghajanian CA. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecologic Oncology. 2008 Aug;110(2):140-5.
Potter KL, Held-Warmkessel J. Intraperitoneal chemotherapy for women with ovarian cancer: Nursing care and considerations. Clinical journal of oncology nursing. 2008 Apr;12(2):265-71.
Dreicer R, Li SL, Manola J, Haas NB, Roth BJ, Wilding G. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the Urothelium (E3800) - A trial of the Eastern Cooperative Oncology Group. Cancer. 2007 Aug;110(4):759-63.
Hess LM, Barakat R, Tian C, Ozols RF, Alberts DS. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 2007 Nov;107(2):260-5.
Winter WE, Maxwell GL, Tian CQ, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology. 2007 Aug;25(24):3621-7.
Bookman MA, McMeekin DS, Fracasso PM. Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group. Gynecologic Oncology. 2006 Nov;103(2):473-8.
Schilder RJ, Blessing JA, Pearl ML, Rose PG. Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. Investigational New Drugs. 2004 Aug;22(3):343-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term PACLITAXEL

PACLITAXEL CARCINOMA CISPLATIN CHEMOTHERAPY CARBOPLATIN STAGE-III TRIAL ovarian cancer CANCER PHASE-III TRIAL TRANSITIONAL-CELL CARCINOMA carboplatin GROUP EXPERIENCE chemotherapy INTRAPERITONEAL CISPLATIN SURVIVAL GYNECOLOGIC-ONCOLOGY-GROUP phase II PROGNOSTIC-SIGNIFICANCE nomogram ALLERGY 6-HYDROXYMETHYLACYLFULVENE PERITONEAL CA-125 II TRIAL phase 2 trial STAGE-III OVARIAN RECURRENT Group PHARMACOKINETICS OVER-EXPRESSION ixabepilone response rate RISK epithelial ovarian cancer VINFLUNINE OVARIAN-CANCER Prognostic markers REGIMEN REPRODUCTIVE AGE-GROUP BREAST-CANCER WOMEN cetuximab clear cell cancer CA-125-mucinous cell cancer-ovarian cancer SINGLE GROUP EPIDERMAL-GROWTH-FACTOR p53 PRETREATMENT CA-125 Urology & Nephrology CETUXIMAB ANAPHYLAXIS PLATINUM-BASED CHEMOTHERAPY progression-free survival at survival REPLACEMENT drug allergy Desensitization-carboplatin-ovarian cancer-skin testing-hypersensitivity ANTIGEN urothelial carcinoma PHASE-II TRIAL GENE-MUTATIONS BLADDER-CANCER EXPERIENCE MORTALITY C-MYC CARCINOMATOSIS MONOCLONAL-ANTIBODY BMI irofulven body weight ANTITUMOR-ACTIVITY KeyWords Plus: SURGERY EXPRESSION paclitaxel MULTICENTER VITRO advanced urothelial cancer DOCETAXEL TRACT MONOCLONAL-ANTIBODIES PHASE-I PHYSICAL-ACTIVITY DRUG endometrial cancer ONCOLOGY-GROUP SURGICAL CYTOREDUCTION PROGNOSTIC-FACTORS INFUSION BODY-MASS INDEX topotecan INTERGROUP TRIAL HYDROXYMETHYLACYLFULVENE CYCLOPHOSPHAMIDE IHC INTRAVENOUS CISPLATIN PLUS Gynecologic Oncology PROTOCOL IFOSFAMIDE sequential PROTEIN CA 125 tumor marker INTRAPERITONEAL Ovarian cancer Overexpression OBESITY 6 months RECEPTOR doublets second-line therapy METHOTREXATE DOUBLETS HIGH-DOSE CARBOPLATIN STANDARD PLATINUM-CONTAINING POSTMENOPAUSAL WOMEN CELL LUNG-CANCER progression-free survival CISPLATIN-BASED CHEMOTHERAPY OVERWEIGHT
Last updated on Wednesday, February 05, 2020